Clinical trials: Residual Disease
Chronic Renal Failure
Initiative for Patient Outcomes in Dialysis - Peritoneal Dialysis (PD) (IPOD-PD Study)
The aim of the study is to asses the hydration status of incident peritoneal dialysis (PD) patients and its evolution over a period of four years, independent of the PD treatment modality (APD or CAPD) and the PD solution type.
- Trial name
- IPOD-PD (NCT01285726)
- Testing
- Non-interventional study
- Where
- 134 sites in Austria, Belgium and 26 more
- Volunteers
- 1,092 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Myocardial Infarction, Echocardiography 2D
Left Ventricular Function After Primary Percutaneous Coronary Intervention: Role of Speckle Echocardiography
Recovery of the left ventricular function is variable from one patient to another, thus assessment of cardiac function by measuring left ventricular ejection fraction using echocardiography is the most common in the daily…
- Conditions
- Myocardial Infarction, Echocardiography 2D, Left Ventricular Dysfunction
- Trial name
- NCT04103008
- Testing
- Speckle tracking echocardiography
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Acute Myeloid Leukemia (AML)
Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure
Venetoclax (Ven) resistance is common in the treatment of acute myeloid leukemia (AML). Patients with Ven resistance have poor response and survival, except those with specific targeted therapy.
- Trial name
- HLA-AML (NCT07813390)
- Testing
- Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA)
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Guangdong Second Provincial General Hospital
Hepatocellular Carcinoma Resectable
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can…
- Trial name
- NCT06157060
- Testing
- circulating tumor DNA
- Where
- 7 sites in China
- Volunteers
- 255 people
- Sponsor
- Zhujiang Hospital
Presbyopia, Refractive Errors
Prospective Multicenter Clinical Study on the Visual and Refractive Outcomes and Safety Outcomes Following Implantation of an AddOn Intraocular Lens in Previously Pseudophakic Eyes
The purpose of this prospective multicenter clinical study is to evaluate the visual and refractive outcomes and safety outcomes following bilateral implantation of trifocal and/or trifocal toric 1stQ AddOn (Medicontur)…
- Conditions
- Presbyopia, Refractive Errors, Residual Astigmatism
- Trial name
- NCT05596682
- Testing
- supplementary intraocular lenses
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 75 people
- Sponsor
- Medicontur Medical Engineering Ltd
Hemophilia A
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)
This Phase III clinical study will assess the impact of BMN 270 (compared to FVIII prophylaxis) on the number of bleeding episodes irrespective of exogenous FVIII replacement treatment in the efficacy evaluation period (EEP)…
- Trial name
- BMN 270-301 (NCT03370913)
- Testing
- valoctocogene roxaparvovec
- Where
- 49 sites in United States, Australia and 11 more
- Volunteers
- 144 people
- Sponsor
- BioMarin Pharmaceutical
Multiple Sclerosis
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers.
- Trial name
- NCT03109288
- Testing
- Cilostazol, Leucovorin, Pirfenidone
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Precursor Lymphoid Neoplasms
Personalized Therapy of Precursor Lymphoid Neoplasms
The primary goal of this study by The Polish Adult Leukemia Group (PALG) is to verify if individual therapeutic approach taking into account biological and phenotypic differences as well as response at the level of minimal…
- Trial name
- NCT01665001
- Testing
- Treatment strategy: induction, consolidation, HSCT, maintenance
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Peripheral Arterial Disease, Atherosclerosis of Extremities
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with…
- Conditions
- Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation
- Trial name
- LEADER-PAD (NCT04774159)
- Testing
- Colchicine 0.5 MG Oral Tablet
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 6,150 people
- Sponsor
- Population Health Research Institute
Acute Lymphoblastic Leukemia
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine whether the bispecific T-cell engager (BiTE®) Blinatumomab (MT103) is effective in the treatment of ALL patients with minimal residual disease.
- Trial name
- NCT00560794
- Testing
- Blinatumomab (MT103)
- Where
- 6 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Amgen Research (Munich) GmbH
Myelodysplastic Syndromes, Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
The goal of this interventional study is to evaluate if pre-emptive intervention using Azacitidine and / or donor lymphocytes or tapering of immune suppression in measurable residual disease (MRD) positive subjects can prevent…
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts, Mixed Myelodysplastic/Myeloproliferative Disease
- Trial name
- NCT05788679
- Testing
- Azacitidine, Donor lymphocytes, Tapering of immune suppression
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Karolinska University Hospital
BPPV, Residual Disease
Effective Treatments for Dizziness After BPPV: A Clinical Study
This clinical study aimed to evaluate how effective vestibular rehabilitation therapy (VRT) and Theta Binaural Beats (T-BB) are in reducing dizziness and anxiety in patients who continue to feel unsteady after successful…
- Conditions
- BPPV, Residual Disease, Vestibular Disease
- Trial name
- NCT06936345
- Testing
- Cawthorne-Cooksey Exercises, Brandt-Daroff Exercises, Theta Binaural Beats
- Where
- Turkey (Türkiye)
- Volunteers
- 56 people
- Sponsor
- Medipol University
Diabetes Mellitus, Type 2, Obesity
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV).
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Gastroparesis
- Trial name
- NCT06533527
- Testing
- GLP-1 medication
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Rectal Cancer
1. SAFE-AI ONCO-TRACK: Multimodal GenAI for Early Detection of Minimal Residual Disease and Recurrence in Gastrointestinal Oncology
Current decision tools (TNM, MRI/PET, CEA, and other serum markers, as well as single-marker genomics) are insufficiently predictive of responders, fail to detect early MRD in many cases, and rarely connect molecular biology to…
- Trial name
- ONCO-TRACK (NCT07189520)
- Testing
- Artificial Intelligence
- Volunteers
- 700 people
- Sponsor
- Università Politecnica delle Marche
Chronic Myelogenous Leukemia
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
The main purpose of the study was to investigate whether nilotinib treatment can be safely suspended with no recurrence of CML in selected patients who responded optimally on this treatment
- Trial name
- ENESTfreedom (NCT01784068)
- Testing
- Nilotinib followed by treatment-free
- Where
- 113 sites in United States, Argentina and 17 more
- Volunteers
- 215 people
- Sponsor
- Novartis Pharmaceuticals
HIV Infections
Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut
The "PLUS" study is a pilot study to measure the effect of therapy intensification (with raltegravir and optional second agent) on HIV levels in the gut and blood in patients on antiretroviral therapy (ART) with viral load < 50…
- Trial name
- PLUS (NCT00884793)
- Testing
- raltegravir, Study NNRTI, Study PI
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of California, San Francisco
Breast Cancer
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA)…
- Trial name
- NCT06401421
- Testing
- ctDNA MRD test
- Where
- 61 sites in United States, Canada
- Volunteers
- 1,800 people
- Sponsor
- Exact Sciences Corporation
Ovarian Neoplasms, Carcinoma, Ovarian Epithelial
Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy
The purpose of this observational study is to learn if a specialized blood test can help predict whether advanced ovarian cancer will return after a patient's initial treatments are finished.
- Conditions
- Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Ovarian Cancer
- Trial name
- NCT07670962
- Testing
- Blood-based ctDNA minimal residual disease (MRD) test
- Volunteers
- 300 people
- Sponsor
- Asan Medical Center
Breast Cancer
MRD in High-risk EBC
This study is a multicenter, prospective, observational cohort study, 125 patients with early-stage high-risk breast cancer will be enrolled, perioperative surgical specimens, peripheral blood specimens before and after adjuvant…
- Trial name
- NCT06566729
- Testing
- Peripheral blood sample collection
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Tinnitus
Tinnitus Related Cerebral Activities
The proposed research is to identify the brain areas activated or deactivated by tinnitus in humans. The identification of these areas is expected to be able to treat tinnitus refractory to traditional therapies by methods of…
- Trial name
- ACCELA (NCT02853812)
- Testing
- Functional brain MRI
- Volunteers
- 24 people
- Sponsor
- University Hospital, Montpellier
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.